Spyre CMO sells 78,333 shares, exercises options
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported coordinated stock trades involving both option exercise and share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported coordinated stock trades involving both option exercise and share sales. On May 1, 2026, Sloan exercised stock options to acquire 78,333 shares of common stock at an exercise price of $27.46 per share.
That same day, Sloan executed multiple open-market sales totaling 78,333 shares of common stock at weighted average prices reported around the low- to mid-$70s per share, with detailed price ranges from $69.21 to $74.96 disclosed in the footnotes. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025.
The option exercised covers a grant originally for 400,000 shares of common stock, with 321,667 option shares remaining outstanding after this exercise and an expiration date of October 1, 2034, subject to continued vesting based on employment.
Insider Trade Summary 10b5-1
Exercise and Sale: 78,333 shares ($3.45M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Sloan Sheldon
Role
Chief Medical Officer
Sold
78,333 shs ($5.60M)
Approx. gross sale proceeds
$5.60M
Approx. exercise cost
$2.15M
Approx. pre-tax spread
$3.45M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 78,333 | $0.00 | $0.00 |
| Exercise | Common Stock | 78,333 | $27.46 | $2.15M |
| Sale | Common Stock | 21,306 | $69.53 | $1.48M |
| Sale | Common Stock | 19,656 | $70.61 | $1.39M |
| Sale | Common Stock | 8,777 | $71.56 | $628K |
| Sale | Common Stock | 12,777 | $72.94 | $932K |
| Sale | Common Stock | 10,358 | $73.74 | $764K |
| Sale | Common Stock | 5,059 | $74.60 | $377K |
| Sale | Common Stock | 400 | $75.37 | $30K |
Holdings After Transaction:
Stock Option (Right to Buy) — 321,667 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (8)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.21 to $70.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.21 to $71.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.21 to $72.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.21 to $73.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.21 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 78,333 shares
Sale price ranges: $69.21–$74.96 per share
Option exercise size: 78,333 shares
+5 more
8 metrics
Shares sold
78,333 shares
Open-market sales of common stock on May 1, 2026
Sale price ranges
$69.21–$74.96 per share
Price ranges for multiple sale transactions, weighted averages reported
Option exercise size
78,333 shares
Common stock acquired via option exercise on May 1, 2026
Option exercise price
$27.46 per share
Exercise price for Stock Option (Right to Buy)
Original option grant
400,000 shares
Right to purchase common stock under option grant
Remaining option shares
321,667 shares
Underlying shares remaining after the reported option exercise
Option expiration
October 1, 2034
Expiration date of the Stock Option (Right to Buy)
10b5-1 plan adoption
June 20, 2025
Adoption date of pre-arranged trading plan for sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting, +1 more
5 terms
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
""expiration_date": "2034-10-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Spyre Therapeutics (SYRE) report for Sheldon Sloan?
Spyre Therapeutics reported that Chief Medical Officer Sheldon Sloan exercised stock options for 78,333 shares at $27.46 per share and sold 78,333 shares of common stock in multiple open-market transactions at weighted average prices in the low- to mid-$70s.
What stock option did Sheldon Sloan exercise at Spyre Therapeutics (SYRE)?
Sloan exercised a Stock Option (Right to Buy) covering 78,333 shares of common stock at an exercise price of $27.46 per share. The option grant originally represented the right to purchase 400,000 shares, subject to a vesting schedule tied to continued employment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates